TISIDB

Summary
Symbol	SLC33A1
Name	solute carrier family 33 (acetyl-CoA transporter), member 1
Aliases	AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location	3q25.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane Multi-pass membrane protein
Domain	PF13000 Acetyl-coenzyme A transporter 1
Function	Probable acetyl-CoA transporter necessary for O-acetylation of gangliosides (PubMed:9096318). Negatively regulates BMP signaling (PubMed:25402622).

> Gene Ontology [ TOP ]
Biological Process	GO:0006818 hydrogen transport GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0015672 monovalent inorganic cation transport GO:0015876 acetyl-CoA transport GO:0015916 fatty-acyl-CoA transport GO:0015992 proton transport GO:0030509 BMP signaling pathway GO:0051181 cofactor transport GO:0051182 coenzyme transport GO:0060395 SMAD protein signal transduction GO:0071772 response to BMP GO:0071773 cellular response to BMP stimulus GO:0072348 sulfur compound transport GO:1901337 thioester transport
Molecular Function	GO:0008521 acetyl-CoA transporter activity GO:0015291 secondary active transmembrane transporter activity GO:0015293 symporter activity GO:0015294 solute:cation symporter activity GO:0015295 solute:proton symporter activity GO:0022804 active transmembrane transporter activity GO:0051184 cofactor transporter activity GO:0051185 coenzyme transporter activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00604 Glycosphingolipid biosynthesis - ganglio series hsa01100 Metabolic pathways
Reactome	R-HSA-425407: SLC-mediated transmembrane transport R-HSA-382551: Transmembrane transport of small molecules R-HSA-425397: Transport of vitamins, nucleosides, and related molecules

Summary
Symbol	SLC33A1
Name	solute carrier family 33 (acetyl-CoA transporter), member 1
Aliases	AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location	3q25.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SLC33A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SLC33A1
Name	solute carrier family 33 (acetyl-CoA transporter), member 1
Aliases	AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location	3q25.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SLC33A1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -1.86; FDR: 0.02370	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SLC33A1
Name	solute carrier family 33 (acetyl-CoA transporter), member 1
Aliases	AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location	3q25.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SLC33A1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.031	0.913
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.067	0.969
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.1	0.936
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.011	0.963
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.245	0.882
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.283	0.894
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.077	0.851
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.038	0.981
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.224	0.895
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.287	0.842
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.353	0.861
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.058	0.244

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SLC33A1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SLC33A1
Name	solute carrier family 33 (acetyl-CoA transporter), member 1
Aliases	AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location	3q25.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC33A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SLC33A1
Name	solute carrier family 33 (acetyl-CoA transporter), member 1
Aliases	AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location	3q25.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC33A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC33A1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SLC33A1
Name	solute carrier family 33 (acetyl-CoA transporter), member 1
Aliases	AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location	3q25.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC33A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SLC33A1
Name	solute carrier family 33 (acetyl-CoA transporter), member 1
Aliases	AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location	3q25.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SLC33A1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SLC33A1
Name	solute carrier family 33 (acetyl-CoA transporter), member 1
Aliases	AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location	3q25.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SLC33A1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SLC33A1
Name	solute carrier family 33 (acetyl-CoA transporter), member 1
Aliases	AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location	3q25.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SLC33A1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SLC33A1